Statins cut heart events in women without heart disease, but not deaths

Statins are among the most prescribed drugs in the world, yet the landmark prevention trials enrolled mostly men, leaving a genuine question about what the drugs do for women who have raised cholesterol but no existing heart disease. Preventing a first heart event and extending life are not the same outcome, and a drug can achieve one without demonstrably achieving the other. For a woman weighing a daily tablet for decades, that distinction matters. This review set out to gather every primary prevention trial that reported results separately for women and ask what the pooled data actually show.

The authors systematically reviewed the published literature for randomised trials of statins in primary prevention, meaning participants had no previous history of cardiovascular disease, that reported sex-specific data for women. Six trials met that bar. From these, the reviewers pooled two outcomes: death from any cause, and any coronary heart disease event. The women in these trials were described as moderately hyperlipidaemic, and statin therapy was given alongside diet and exercise rather than in isolation, which reflects how the drugs are actually prescribed.

On coronary heart disease events, statins delivered: the pooled risk ratio was 0.78, a statistically significant reduction in first heart events for women without prior cardiovascular disease. On all-cause mortality the picture was different: the summary risk ratio was 0.90, but the result fell well short of statistical significance, so no survival benefit was demonstrated. The authors' conclusion separates the two outcomes cleanly, describing significant benefit in preventing coronary heart disease events but no proven benefit in preventing death from any cause in this population.

The reduction in events aligns broadly with what statin trials show in mixed and male-dominated populations, which is reassuring given how underrepresented women were in this research. The mortality null is harder to interpret: it may reflect a genuine absence of survival benefit in lower-risk women, or simply too few deaths across six trials to detect one. The analysis dates from 2010, so it predates later evidence, and it cannot say how the balance shifts with age, baseline risk or years of treatment. Those remain live questions in women's cardiovascular prevention.

For a woman considering statins purely for prevention, this is a reason to frame the decision around avoiding heart events rather than living longer, because only the first had trial support here. It is also a reminder that sex-specific evidence can differ from headline trial results, and that asking what the data show for people like you is a legitimate question to put to a clinician. None of this replaces an individual risk assessment, and the analysis itself is an older one, so newer evidence may refine the picture.